{"id":"transcon-hgh","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Hypersensitivity reaction"},{"rate":"null","effect":"Gallbladder disease"}]},"_chembl":{"chemblId":"CHEMBL4297687","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This allows for once-weekly dosing, mimicking the natural pulsatile secretion of hGH. TransCon hGH is designed to provide sustained growth hormone levels, potentially improving growth outcomes in patients with growth hormone deficiency.","oneSentence":"TransCon hGH is a long-acting human growth hormone (hGH) analog that uses a proprietary technology called TransCon to extend its half-life.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:43.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of growth hormone deficiency in children and adults"}]},"trialDetails":[{"nctId":"NCT05775523","phase":"","title":"A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","status":"RECRUITING","sponsor":"Ascendis Pharma Endocrinology Division A/S","startDate":"2023-03-20","conditions":"Growth Hormone Deficiency","enrollment":500},{"nctId":"NCT05171855","phase":"PHASE3","title":"A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ascendis Pharma Endocrinology Division A/S","startDate":"2021-12-16","conditions":"Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency","enrollment":220},{"nctId":"NCT04615273","phase":"PHASE3","title":"A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ascendis Pharma Endocrinology Division A/S","startDate":"2020-12-03","conditions":"Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency","enrollment":264},{"nctId":"NCT03344458","phase":"PHASE3","title":"A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial","status":"COMPLETED","sponsor":"Ascendis Pharma A/S","startDate":"2017-12-19","conditions":"Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency","enrollment":298},{"nctId":"NCT03305016","phase":"PHASE3","title":"A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ascendis Pharma Endocrinology Division A/S","startDate":"2017-11-13","conditions":"Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency","enrollment":146},{"nctId":"NCT02781727","phase":"PHASE3","title":"A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)","status":"COMPLETED","sponsor":"Ascendis Pharma Endocrinology Division A/S","startDate":"2016-12-13","conditions":"Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases","enrollment":162},{"nctId":"NCT04326374","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Visen Pharmaceuticals (Shanghai) Co., Ltd.","startDate":"2019-12-30","conditions":"Growth Hormone Deficiency, Endocrine System Diseases, Hormones","enrollment":150},{"nctId":"NCT01247675","phase":"PHASE2","title":"A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ascendis Pharma A/S","startDate":"2010-11","conditions":"Adult Growth Hormone Deficiency","enrollment":37},{"nctId":"NCT01010425","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)","status":"COMPLETED","sponsor":"Ascendis Pharma A/S","startDate":"2009-11","conditions":"Healthy","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACP-011"],"phase":"phase_3","status":"active","brandName":"TransCon hGH","genericName":"TransCon hGH","companyName":"Ascendis Pharma A/S","companyId":"ascendis-pharma-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TransCon hGH is a long-acting human growth hormone (hGH) analog that uses a proprietary technology called TransCon to extend its half-life. Used for Treatment of growth hormone deficiency in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}